The seeds of therapeutic conservativism trace their roots back to Hippocrates. He states Life is short, art long......and experiment perilous. The true problem lies in the novelty of GTCB's platform. Medical people including drug manufacturers are reluctant to embrace any sweepingly new technology until others have validated it clinically. The potential risks are precieved to outway the potential advantages until proven otherwise. Its not that GTCB's science isnt better. The chances are overwhelming that it is, its simply that GTCB must work through this initertia, which IMHO they will. .....
Market Data 
Markets 
AI
